A 24-Week, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of Toujeo and Tresiba in Insulin-Naive Patients with Type 2 Diabetes Mellitus Not Adequately Controlled with Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 03 Aug 2017
At a glance
- Drugs Insulin glargine (Primary) ; Insulin degludec
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Sanofi
- 15 Jun 2017 Planned End Date changed from 1 Oct 2017 to 18 Aug 2017.
- 15 Jun 2017 Planned primary completion date changed from 1 Oct 2017 to 18 Aug 2017.
- 10 Jun 2017 Biomarkers information updated